Non-compressible bleeding from the aorta, iliacs, and other major vasculature is a life-threatening event during trauma, childbirth, and other conditions/procedures. Basic retrograde balloon occlusion of the aorta (REBOA) technologies have been used to temporarily control bleeding. However, basic REBOA technologies do not ensure confident placement without x-ray, balloon security during resuscitation, and other clinical feedback to the clinicians.
Emergency Scientific’s Scout Occlusion Balloon platform provides new features to help the clinician access the aorta, confirm landing zone 1 or 3, confirm placement security, inflate, and monitor the patient. The market is supported by existing CPT 37244 reimbursement (2019 Avg $9,750) and clinician desire for new solutions. The company expects FDA submission in 2020 with support from a Dept. of Defense agency. Raising seed funding March 2020.